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AbsTrACT
Objective To determine the prevalence of antibodies to 
epstein- Barr virus (eBV) in a large cohort of patients with 
early multiple sclerosis (Ms).
Methods serum samples were collected from 901 
patients with a clinically isolated syndrome (cis) or 
early relapsing–remitting multiple sclerosis (rrMs) 
participating in the german national Ms cohort, a 
prospective cohort of patients with early Ms with 
stringent inclusion criteria. epstein- Barr nuclear antigen 
(eBna)-1 and viral capsid antigen (Vca) antibodies 
were measured in diluted sera by chemiluminescence 
immunoassays (clias). sera of eBna-1 and Vca 
antibody- negative patients were retested undiluted by an 
eBV igg immunoblot. For comparison, we retrospectively 
analysed the eBV seroprevalence across different age 
cohorts, ranging from 0 to >80 years, in a large hospital 
population (n=16 163) from Berlin/northern germany.
results eBna-1 antibodies were detected by clia in 
839 of 901 patients with cis/rrMs. Of the 62 patients 
without eBna-1 antibodies, 45 had antibodies to Vca 
as detected by clia. in all of the remaining 17 patients, 
antibodies to eBV were detected by immunoblot. 
altogether, 901 of 901 (100%) patients with cis/rrMs 
were eBV- seropositive. eBV seropositivity increased with 
age in the hospital population but did not reach 100% in 
any of the investigated age cohorts.
Conclusion The complete eBV seropositivity in this 
large cohort of patients with early Ms strengthens the 
evidence for a role of eBV in Ms. it also suggests that 
a negative eBV serology in patients with suspected 
inflammatory central nervous system disease should alert 
clinicians to consider diagnoses other than Ms.
InTrOduCTIOn
Strong and consistent evidence indicates an associ-
ation of multiple sclerosis (MS) and infection with 
the Epstein- Barr virus (EBV).1–3 This led to the 
proposal that, from an epidemiological perspective, 
MS could be regarded as a late complication of EBV 
infection.4 If this was true, one would expect that 
there should be practically no EBV- seronegative 
patients with MS.5 Previous seroepidemiological 
studies and meta- analyses thereof indeed observed 
very high EBV seropositivity rates (~98% to 
100%) in patients with MS or a clinically isolated 
syndrome (CIS).1 6–11 Nevertheless, the detection 
of few EBV- seronegative persons with a diagnosis 
of MS in some of those studies suggests that EBV- 
seronegative MS may occur. However, as inclusion 
criteria of previous studies on the seroprevalence 
of EBV in patients with MS were heterogeneous, it 
cannot be excluded that EBV- seronegative persons 
with a diagnosis of MS reported in the literature 
may occasionally have been misclassified and could 
in fact have diagnoses other than MS.8 Further-
more, it was shown that the EBV seroprevalence 
in patients with MS may depend on the sensitivity 
and specificity of the applied antibody assays and 
that in the likely most robust studies, that is, those 
that used two independent methods for detection of 
EBV antibodies, EBV seropositivity in patients with 
a diagnosis of MS may reach 100%.7
To systematically search for EBV- seronegative 
patients with MS, we analysed the EBV seroprev-
alence in 901 patients of the German National MS 
cohort, a prospective longitudinal observational 
cohort of patients with early MS with stringent 
inclusion criteria. For comparison, we retrospec-
tively determined EBV seroprevalence rates across 
different age cohorts in a large hospital population 
(N=16 163) from Berlin/Northern Germany.
PATIenTs And MeThOds
Patients with early Ms
The German National MS cohort is a multicentre 
prospective longitudinal observational cohort 
which recruited a total of 1212 patients between 
August 2010 and December 2014.12 Inclusion 
criteria have previously been reported in detail and 
comprise female and male patients aged ≥18 years 
and
 ► A diagnosis of a CIS (defined as a first clinical 
event suggestive of inflammatory demyelina-
tion) within 6 months before inclusion and 
fulfilment of three of four Barkhof criteria.
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 ► A diagnosis of a CIS within 6 months before inclusion and 
fulfilment of two of four Barkhof criteria and intrathecal 
IgG production in cerebrospinal fluid (CSF) or abnormal 
visually evoked potentials.
 ► A diagnosis of a CIS within 6 months before inclusion and 
fulfilment of the McDonald 2010 criteria for relapsing–
remitting multiple sclerosis (RRMS).
 ► A diagnosis of RRMS based on the McDonald 2005 criteria 
within 2 years before inclusion.12
Exclusion criteria comprise previous use of any disease- 
modifying therapy for MS (except for short- term relapse 
treatment), primary or secondary progressive MS, concurrent 
progressive neurological diseases and conditions interfering with 
the assessment plan, for example, contraindications to MRI. The 
assessment plan includes standardised collection of demographic 
and clinical data, assessment of the Expanded Disability Status 
Scale (EDSS) score and standardised sampling of biospecimens. 
All patients were recruited at specialised MS centres and study 
data were monitored with a query system.
Sera from therapy- naïve patients were collected, centrifuged 
and aliquoted during the baseline visit at the participating centres 
according to standard operating procedures and were shipped 
overnight to the Department of Neurology, Technische Univer-
sität München, where they were stored at −80°C. Baseline 
serum samples of 901 patients were available for EBV antibody 
testing and were sent on dry ice to the Department of Neurology, 
Charité – Universitätsmedizin Berlin.
detection of ebV antibodies
Serum IgG antibodies to Epstein- Barr nuclear antigen (EBNA)-1 
and to the EBV viral capsid antigen (VCA) were measured by 
Liaison (DiaSorin, Saluggia, Italy) automated quantitative chemi-
luminescence immunoassay (CLIA) at Labor Berlin GmbH, 
Berlin, Germany. As only limited amounts of serum (~50 µL) 
from participants of the German National MS cohort were 
available, all sera had to be measured in dilution. EBNA-1 IgG 
antibodies were measured in serum samples diluted either 1:20 
(n=40) or 1:10 (n=861) in assay dilution buffer. With these 
dilutions, EBNA-1 IgG levels <3 U/mL were considered nega-
tive, and EBNA-1 IgG levels ≥3 U/mL were considered positive. 
All EBNA-1 IgG- negative serum samples were tested at a dilu-
tion of 1:10 in assay dilution buffer for antibodies to VCA. With 
this dilution, VCA IgG levels <10 U/mL were considered nega-
tive and VCA IgG levels ≥10 U/mL were considered positive. 
As per the manufacturer’s instructions, the assay range of the 
EBNA-1 IgG CLIA is 3–600 U/mL and that of the VCA IgG CLIA 
is 10–750 U/mL.
Since we had to determine EBNA-1 and VCA IgG by CLIA in 
diluted sera of participants of the German National MS cohort, 
we retested EBNA-1 and VCA IgG- negative sera without dilution 
by an EBV IgG immunoblot (recomLine EBV IgG, Mikrogen, 
Germany). As only a small volume of serum (20 µL) is needed for 
the EBV IgG immunoblot, we were able to use undiluted sera for 
these measurements. Serum samples that were positive in at least 
one of the three assays (EBNA-1 IgG CLIA, VCA IgG CLIA or 
EBV IgG immunoblot) were considered EBV seropositive.
retrospective analysis of ebV seroprevalence in a large 
hospital population
We retrospectively analysed results of EBV serologies, which 
were performed for routine diagnostic purposes in 16 163 
persons at Labor Berlin GmbH, Berlin, Germany, between 
January 2014 and December 2016. Sera were sent for EBV 
serological testing from persons treated as inpatients or outpa-
tients at university hospitals (Charité – Universitätsmedizin 
Berlin) located in Berlin or community hospitals located 
in Berlin and Northern Germany. The 16 163 persons were 
included irrespective of diagnoses or the reason for ordering 
EBV serologies. For individuals tested more than once during 
the study period, only the results of the first EBV serology 
were considered. From all persons included in the analysis, 
results of serological tests for EBNA-1 IgG and VCA IgG 
and VCA IgM had to be available. Notably, EBNA-1 IgG is 
a marker of past EBV infection, VCA IgG can be found in 
primary and past EBV infections, and VCA IgM is a marker of 
primary EBV infection.13 Testing for EBNA-1 IgG, VCA IgG 
and VCA IgM was performed by Liaison automated quanti-
tative CLIA using undiluted sera. Thus, the same method 
(Liaison CLIA) was used for testing of patients with CIS/
RRMS and patients of the hospital population, with sera 
of patients with CIS/RRMS being measured in dilution and 
sera of patients from the hospital population being measured 
without dilution. According to the manufacturer’s recom-
mendations, in undiluted sera, EBNA-1 IgG levels <5 U/mL 
were considered negative, levels between 5 and 20 U/mL were 
considered equivocal and levels ≥20 U/mL were considered 
positive; VCA IgG levels <20 U/mL were considered negative 
and VCA IgG levels ≥20 U/mL were considered positive; and 
VCA IgM levels <20 U/mL were considered negative, levels 
between 20 and 40 U/mL were considered equivocal and VCA 
IgM levels≥ 40 U/mL were considered positive. Persons with 
EBNA-1 IgG and VCA IgG and VCA IgM below the respective 
cut- offs were considered EBV- seronegative. Persons in whom 
at least one of the three antibodies, EBNA-1 IgG, VCA IgG or 
VCA IgM, was above the respective cut- offs were considered 
EBV- seropositive. From the age of 5 years onwards, persons 
were grouped in 5- year age cohorts. To analyse the EBV sero-
prevalence in early life in more detail, newborns and infants 
below 5 years of age were grouped in smaller age cohorts.
statistical analyses
Continuous data were summarised using medians and IQRs. 
Categorical data are reported as absolute and relative frequen-
cies (%). The significance of different EBV seropositivity rates 
between patients with early MS and persons in the hospital 
population was assessed by two- tailed Fisher exact tests 
(https://www. graphpad. com/ quickcalcs/ contingency2/). A p 
value of <0.05 was considered significant.
resulTs
ebV seroprevalence in early Ms
The median (IQR) age of the 901 patients included in this study 
was 33 (27–41) years, and 630/901 (69.9%) were women. At 
the time of blood sampling, 380 (42.2 %) had a diagnosis of a 
CIS and 521 (57.8%) had a diagnosis of RRMS according to 
the inclusion criteria of the German National MS cohort. The 
median (IQR) EDSS score of patients with CIS and RRMS was 
1.5 (1.0–2.0, data available from n=899 patients).
IgG antibodies to EBNA-1, as measured in diluted sera by 
CLIA, were positive in 839 of 901 (93.1%) patients with CIS/
RRMS. Of the 62 patients without antibodies to EBNA-1, 45 
(72.6%) had positive IgG antibodies to VCA, as measured in 
diluted sera by CLIA. Of the 17 remaining patients, 17 (100%) 
had IgG antibodies to EBV as detected in undiluted sera by 
EBV IgG immunoblot. Detailed results of EBV IgG immuno-
blots are provided in online supplementary table 1. In sum, 12 
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Figure 1 (a) eBV seropositivity rates by age cohorts in a large hospital population (n=16 163). The percentage positivity of igg antibodies to eBna-1 and 
of igg and igM antibodies to Vca in different age cohorts is shown. note that the x- axis is not proportional. eBV seropositivity was defined as seropositivity 
to at least one of the three antibodies, eBna-1 igg, Vca igg or Vca igM. The number of persons analysed in each age cohort is indicated above the graph. 
(B) eBV seropositivity rates by age cohorts in a large hospital population are shown separately for female (n=7714) and male (n=8322) persons. eBV 
seropositivity was defined as seropositivity to at least one of the three antibodies, eBna-1 igg, Vca igg or Vca igM. The number of female/male persons 
analysed in each age cohort is indicated above the graph. eBna-1, epstein- Barr nuclear antigen-1; eBV, epstein- Barr virus; Vca, viral capsid antigen.
of 17 sera reacted with the EBNA-1 p72 antigen and 17 of 17 
sera reacted with at least one of two VCA antigens (p18 and 
p23) included in the EBV IgG immunoblot. Altogether, 901 of 
901 (100%) patients with CIS/RRMS investigated in this work 
were EBV seropositive.
ebV seroprevalence in a large hospital population
To compare the EBV seroprevalence in patients with early MS 
with the general EBV seroprevalence in a similar geographical 
region, we analysed the EBV seroprevalence across different age 
groups in a large hospital population (n=16 163) from Berlin/
Northern Germany. Data on sex were available from 16 036 
of these persons, of which 7714 (48%) were female and 8322 
(52%) were male. Figure 1A summarises the EBV seropreva-
lence in the entire hospital population; the respective source 
data are provided in online supplementary table 2. EBV sero-
positivity was high in newborns (<0.25 years) and lowest in 
0.75–<1 year olds. Subsequently, EBV seropositivity increased 
until adulthood, with steepest increases in the age cohorts of 
1.5–2.0 and 15–19 years. The increases of EBV seropositivity 
in these age cohorts were paralleled by an increased detection 
of VCA IgM antibodies, indicating primary EBV infections. 
While EBV seropositivity further increased with increasing age 
and was ≥98% in all 5- year age cohorts from 45 to 79 years, 
it did not reach 100% in any of these age cohorts. EBV sero-
positivity tended to be overall slightly higher in women than in 
men, but the course of EBV seropositivity across the life span 
was similar in both sexes (figure 1B).
When comparing the EBV seropositivity rates in patients 
with early MS and in participants of the hospital population 
in the age range of 20–40 years, that is, the typical age of 
clinical onset of MS,14 EBV seropositivity among patients with 
MS (610/610, 100%) was higher than among participants of 
the hospital population (4134/4343, 95.2%; p<0.0001). In 
a comparison of EBNA-1 IgG seropositivity by age between 
patients with early MS and patients from the hospital popula-
tion, the difference in EBNA-1 IgG seropositivity was stron-
gest in the youngest analysed age cohort (20–24 years) and 
subsequently declined with increasing age (online supplemen-
tary figure 1).
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dIsCussIOn
The key result of this study is a complete EBV seropositivity in 
a large cohort (n=901) of patients with early MS. While this 
finding is consistent with the known high EBV seroprevalence in 
MS,1 6–11 the absence of any EBV- seronegative patients with early 
MS in our cohort appears remarkable and further strengthens 
the evidence for an association of EBV infection and MS. The 
already 100% EBV seropositivity in the 380 patients with a CIS, 
that is, the earliest clinically detectable manifestation of MS, 
complies with the concept that EBV infection precedes the clin-
ical onset of MS and suggests that EBV exerts its role early in the 
development of MS.15
The German National MS cohort is a prospective longitudinal 
cohort with stringent inclusion criteria, requiring MRI, CSF or 
electrophysiological evidence supportive of MS in patients with 
a CIS.12 Thus, the likelihood of inclusion of patients not having 
a true CIS, that is, a CIS as a first clinical manifestation of MS, or 
not having true MS into this well- characterised cohort of patients 
with CIS/early RRMS appears very low. Assuming that there is 
a genuine association of EBV and MS, the high degree of diag-
nostic certainty in patients participating in the German National 
MS cohort may therefore explain the 100% EBV seropositivity 
observed in this cohort. This conclusion is supported by findings 
of a previous meta- analysis, which in a post hoc analysis found 
higher ORs for EBNA-1 and VCA IgG seropositivity in serolog-
ical studies of EBV prevalence in MS that included confirmed 
cases of MS as compared with studies that included confirmed 
and probable cases of MS.8 The most plausible explanation for 
this observation is that probable cases of MS are more likely to 
comprise misclassified patients who actually do not have MS. 
The EBV seroprevalence of those misclassified patients would 
be expected to correspond to that of the general population and 
to thus be lower than the EBV seroprevalence of patients with 
true MS, which could explain the occasional detection of EBV- 
seronegative persons in some former studies on EBV seropreva-
lence in MS.8
Our study corroborates results obtained in 1047 retrospectively 
collected patients with a CIS, only one of whom was found to be 
EBV seronegative.10 16 Altogether, the present evidence suggests 
that EBV- seronegative patients with MS, if they should exist at 
all, occur extremely rarely. An implication of these findings of 
relevance for clinical practise is that a negative EBV serology in 
a patient with suspected inflammatory central nervous system 
disease should alert clinicians to consider diagnoses other than 
MS.2 5 7 Given that the difference in the EBV seropositivity rates 
between patients with MS and controls declines with age (see 
also online supplementary figure 1), the younger the age of the 
patient, the more informative testing for EBV should be. Future 
studies on this issue may therefore focus in particular on children 
with suspected inflammatory central nervous system disease, as 
the difference between the likewise high EBV seroprevalence 
in children with MS and the EBV seroprevalence in paediatric 
controls is rather pronounced.17
The high EBV seropositivity in newborns and the rapid 
decline until the age of 1 year observed in the hospital popu-
lation is explained by placental transmission and subsequent 
disappearance of maternal EBV antibodies. The subsequent 
steep increases of EBV seropositivity in early infancy and in the 
age cohort of 15–19 years correspond to previous data on the 
natural course of EBV infection in industrialised countries of 
the northern hemisphere.18–21 The somewhat higher seropreva-
lence of VCA IgG as compared with EBNA-1 IgG in patients of 
the hospital population is consistent with findings of previous 
large seroepidemiological studies and likely related to the known 
phenomenon that a certain proportion of persons infected with 
EBV does not develop antibodies to EBNA-1.8 13 22 Importantly, 
we found that about 30% of 10–14 year olds in our hospital 
population from Northern Germany were EBV seronegative. 
This is of relevance as these individuals are particularly prone 
to develop symptomatic primary EBV infection in the form of 
infectious mononucleosis, which is associated with an about 
twofold increased risk of MS.23 24
The higher EBV seropositivity rate in patients with early 
MS (100%) as compared with persons in the hospital popula-
tion (95.2%) in the age range of 20–40 years is consistent with 
previous data8 and appears compatible with the concept that 
EBV may be a necessary but not sufficient factor for the devel-
opment of MS.
Of note, due to only limited amounts of serum available, sera 
of patients from the MS cohort had to be measured by CLIA in 
dilution. All EBNA-1 and VCA antibody- negative patients with 
CIS/early RRMS, as determined in diluted sera by CLIA, were 
thus retested by an EBV IgG immunoblot, which requires only 
a small volume of serum, enabling us to analyse undiluted sera. 
Detection of EBV antibodies by immunoblot in patients, who 
were EBV and VCA IgG negative by CLIA, is therefore explained 
by the fact that those sera were measured undiluted, that is, at a 
10- fold higher concentration than in the CLIA. The majority of 
the 17 sera tested by the EBV immunoblot contained antibodies 
to EBNA-1, and all 17 sera contained antibodies to VCA (see 
online supplementary table 1), further supporting the conclu-
sion that antibody responses in those 17 patients differed only 
quantitatively but not qualitatitvely from that of the other 884 
patients.
Of further note, unlike patients with CIS/RRMS, EBV- 
seronegative participants of the hospital population, as deter-
mined by CLIA using undiluted sera, were not retested by an 
EBV immunoblot. We consider it very unlikely that this could 
have resulted in a higher rate of EBV seronegativity in the 
hospital population than in patients with MS for the following 
reasons: first, in routine diagnostic serology, absence of EBNA-1 
IgG, VCA IgG and VCA IgM, as determined by CLIA in undi-
luted sera, is generally accepted to reliably indicate EBV seroneg-
ativity with no further confirmatory tests being required.13 21 25 
Second, while we are not aware of published studies that directly 
compared the recomLine EBV IgG immunoblot with the liaison 
CLIA applied in our work, in a previous comparative study, 
the sensitivity of the recomLine EBV IgG immunoblot was not 
higher than that of another CLIA method (Architect; Abbott, 
Wiesbaden, Germany),25 which is similar to the CLIA Method 
used in our work.26 Third, when we re- tested 28 sera, which 
were EBNA-1 IgG and VCA IgG negative, as determined in 
undiluted sera by the Liaison CLIA, by EBV immunoblots, all 
of these sera were likewise EBV seronegative in the EBV immu-
noblot (unpublished observation). Altogether, the available 
evidence therefore clearly argues against a higher sensitivity of 
the EBV IgG immunoblot as compared with determination of 
EBNA-1 IgG and VCA IgG in undiluted sera by the liaison CLIA.
A limitation of this study is that we did not determine EBV sero-
prevalence in the general population, but, similar to a previous 
large investigation,21 used a hospital population as a surrogate 
instead. The hospital population may have included patients in 
whom EBV serologies were ordered for a suspected primary EBV 
infection, which could potentially result in higher EBV sero-
positivity rates than in the general population. Conversely, our 
hospital population may also have included immunosuppressed 
patients in whom EBV serologies could potentially result false 
5abrahamyan s, et al. J Neurol Neurosurg Psychiatry 2020;0:1–6. doi:10.1136/jnnp-2020-322941
Multiple sclerosis
negative. However, given the very high number of patients anal-
ysed, it seems conceivable that the data obtained in the hospital 
population are overall representative of EBV seropositivity rates 
across different age ranges in the general population. Finally, as 
is the case with every serological test, we cannot exclude the 
occurrence of rare false- positive results. Nevertheless, such rare 
false- positive results would be highly unlikely to explain the 
100% EBV seropositivity observed in patients with CIS/RRMS 
in our study.
COnClusIOn
The complete EBV seropositivity in this large cohort of patients 
with CIS/RRMS strengthens the evidence for a role of EBV in 
MS. It also suggests that a negative EBV serology in patients with 
suspected inflammatory central nervous system disease should 
alert clinicians to consider diagnoses other than MS. The results 
of this study are compatible with the concept that MS could be 
a rare late complication of EBV infection. Future studies should 
focus on the clarification of the mechanisms underlying the role 
of EBV in MS.
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